Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07114939
PHASE1

FTT PET/CT in Pancreatic Neuroendocrine Tumors

Sponsor: Abramson Cancer Center at Penn Medicine

View on ClinicalTrials.gov

Summary

A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). A total of 12 patients will be enrolled. Patients will undergo a study imaging assessment using a whole-body PET CT scanner. Dynamic images will be obtained beginning immediately prior to the administration of 10 mCi of \[18F\]FTT (±20%) for a total of 60 minutes. A static scan may subsequently be obtained up to 90 minutes post radiotracer injection, per the PI's discretion. \[18F\]FTT uptake will be measured on the PET scan and correlated with two molecular outcomes.

Official title: PARP-1 Targeting With the Novel Radiotracer [18F]FTT in Pancreatic Neuroendocrine Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2025-10-01

Completion Date

2027-09

Last Updated

2026-02-02

Healthy Volunteers

No

Interventions

DRUG

[18F]FluorThanatrace

Intravenous injection of ≤ 12 mCi of \[18F\]FTT for whole-body PET CT dynamic imaging and subsequent static scan.

Locations (1)

University of Pennsylvania, Perelman Center for Advanced Medicine

Philadelphia, Pennsylvania, United States